Cytosorbents Corporation (CTSO)

Market Cap	67.78M
Revenue (ttm)	36.11M
Net Income (ttm)	-9.87M
Shares Out	62.76M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,270
Open	1.050
Previous Close	1.060
Day's Range	1.040 - 1.095
52-Week Range	0.710 - 1.610
Beta	1.20
Analysts	Buy
Price Target	5.50 (+409.26%)
Earnings Date	Aug 7, 2025

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, su...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 149
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2024, Cytosorbents's revenue was $35.59 million, an increase of 14.51% compared to the previous year's $31.08 million. Losses were -$20.72 million, -29.16% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CTSO stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 409.26% from the latest price.

Price Target

$5.5

(409.26% upside)

Analyst Consensus: Buy